Vera Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VERA Nasdaq 8731 https://veratx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vera Therapeutics Inc

Should You Buy Vera Therapeutics (VERA) Ahead of Earnings? - May 11th, 2023 12:36 pm
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results - May 11th, 2023 11:30 am
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs - May 4th, 2023 12:00 pm
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 28th, 2023 11:30 am
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference - Feb 27th, 2023 9:05 pm
Chief Financial Officer Sean Grant Just Bought 207% More Shares In Vera Therapeutics, Inc. (NASDAQ:VERA) - Feb 14th, 2023 12:48 pm
With 35% stake, Vera Therapeutics, Inc. (NASDAQ:VERA) seems to have captured institutional investors' interest - Feb 9th, 2023 10:54 am
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock - Feb 6th, 2023 9:05 pm
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - Feb 2nd, 2023 2:52 am
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock - Feb 1st, 2023 9:01 pm
Vera Therapeutics Releases Interim Analysis Of Rare Kidney Disease Drug, Deprioritizes Certain Phase 3 Programs - Jan 30th, 2023 12:35 pm
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria - Jan 30th, 2023 11:00 am
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN) - Jan 25th, 2023 1:00 pm
Why Vera Therapeutics Stock Bolted Higher This Week - Jan 22nd, 2023 12:39 pm
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax - Jan 6th, 2023 10:02 am
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped - Jan 4th, 2023 9:07 pm
VERA Dips Despite Positive Data From IgA Nephropathy Study - Jan 4th, 2023 5:20 pm
These 2 Nasdaq Biotechs Are Making Big Moves Wednesday - Jan 4th, 2023 3:22 pm
Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study - Jan 4th, 2023 11:52 am
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy - Jan 3rd, 2023 9:01 pm